Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A combination of two immunotherapy drugs may be more effective than the current standard treatment, chemotherapy.
Checkpoint inhibitor doubled disease-free survival time after surgery.
Opdivo plus chemotherapy led to a significant improvement in overall survival.
The decrease is largely due to improved lung cancer treatment, but the impact of COVID-19 is not yet known.
Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.
Opdivo and Keytruda are potential alternatives to current first-line therapies.
Any amount of alcohol can increase a person’s risk for several types of cancer, including cancers of the throat, esophagus, and liver.
Delays in screening, diagnosis and treatment could lead to poorer outcomes.
Checkpoint inhibitor extended survival by about three months compared with chemotherapy.
Many people with GI cancers are diagnosed only after the disease has spread through the body, so this test could aid in early detection.
A consortium of health providers and researchers hopes to raise public awareness of how exercise can benefit those living with cancer.
pembrolizumab’s efficacy was investigated in two clinical trials of people with recurrent, locally advanced or metastatic disease.
A low dose of platinum-based chemotherapy worked as well as higher doses for elderly and frail people with esophageal and stomach cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.